This is the first generic available for Revlimid in the United States.
Teva Pharmaceuticals launched lenalidomide, the first generic version of Celgene Corp.’s blockbuster cancer treatment Revlimid (lenalidomide capsules).
Revlimid, which treats multiple myeloma in combination with dexamethasone (Decadron, other brand names), myelodysplastic syndromes (specifically patients with a deletion of some part of chromosome 5), and mantle cell lymphoma, had annual sales of $2.3 billion as of 2021, according to IQVIA, Teva said in a news release.
Lenalidomide capsules will be available immediately in the United States in 5 mg, 10 mg, 15, mg, and 25 mg strengths. The drug also treats certain myelodysplastic syndromes.
“The launch of our first generic version of Revlimid in the United States provides patients with another important treatment option for these extremely challenging conditions, demonstrating Teva’s commitment to making complex generic drugs available to the patients who need them,” said Christine Baeder, senior vice president and chief operating officer of U.S. generics at Teva USA.
Lenalidomide adds to Teva’s generic portfolio of oncology treatments, which accounts for 73% of the essential medicines in this category, according to the company.
Additionally, Sandoz recently announced that it has launched a generic of lenalidomide in 19 countries across Europe.
The First Financial Toxicity Tumor Board Reports Success in Individual Patient Savings
May 14th 2025Financial toxicity can affect patient outcomes and quality of life. For example, a patient may forgo treatment or medications to save money, or they may incur high medical debt or go into bankruptcy to pay for medical care.
Read More
Is Arkansas’ New PBM Law the Right Path Forward for Reform? No One Knows Yet
May 9th 2025It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen